News | November 12, 2025
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
e brings over 27+ years of rich pharmaceutical experience
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Subscribe To Our Newsletter & Stay Updated
